Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

McNeil Tylenol for pain, aspirin for heart ad claims supported, NAD says to AFA challenge.

This article was originally published in The Tan Sheet

Executive Summary

McNEIL TYLENOL FOR PAIN, ASPIRIN FOR HEART AD MESSAGE SUPPORTED, NAD CONCLUDES in a case report issued Sept. 11 on a challenge against Tylenol ads brought by the Aspirin Foundation of America. The National Advertising Division of the Council of Better Business Bureaus says the advertised statement that people taking aspirin for its cardiovascular benefits should take "Aspirin for your heart, Tylenol for your pain" does not "convey an implied claim that aspirin is not effective or less effective." Rather, the watchdog group said, "it is the bottom line message of the advertising reminding the targeted group to use Tylenol for pain relief rather than aspirin because of associated concerns about stomach irritation -- a provable claim that, as used in these ads, is supported."

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS087533

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel